. Author manuscript; available in PMC: 2024 Aug 1.

Published in final edited form as: Fundam Clin Pharmacol. 2023 Mar 25;37(4):726–738. doi: 10.1111/fcp.12889

Table 3.

Activities toward variants based on cytopathogenic reduction (^aEC₅₀) or viral replication (^bIC50)

Drug/metabolite	Alpha	Beta	Gamma	Delta	Omicron B1	Omicron B2	GHB
Molnupiravir	3.6^a				1.9^a		3.9^a
NHC	2.3^a, 0.34^b	1.5^a	2.0^a, 0.24^b	3.3^a, 0.29^b	0.34^b	0.46^b	2.2^a
Nirmatrelvir	0.28^a, 1.78 ^b	0.14^a	0.28^a, 1.65^b	0.21^a, 1.80^b	0.14^a	1.9^b	0.11^a
Remdesivir	0.077^a	0.063^a	0.074^a		0.048^a		0.05^a
GS-441524	0.76^a	0.77^a	0.90^a	0.87^a	0.50^a		0.81^a

NHC: N-hydroxycytidine, the hydrolytic metabolite of molnupiravir; GS-441524: major metabolite of remdesivir in the blood.

[86];